BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to DLD-1 cell line is 50
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DPP4 | 3009 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0085 | 31285270 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.211 | 31285270 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0753 | 31285270 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | Western Blotting followed by SFA | NA | 0.64 | 0.0753 | 31964531 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | RT-PCR followed by SFA | NA | 0.64 | 0.0753 | 32066912 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by qPCR | NA | 0.64 | 0.0753 | 29449559 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.64 | 0.0753 | 23418515 |
| KLF4 | 6348 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and IF staining | NA | 0.44 | 0.0891 | 23418515 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs and Western Blotting followed by SFA | NA | 0.4 | 0.7582 | 31964531 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by qPCR | NA | 0.4 | 0.7582 | 29449559 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.4 | 0.7582 | 23418515 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs | NA | 0.4 | 0.7582 | 24760019 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by SFA | NA | 0.4 | 0.7582 | 21694723 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by SFA | NA | 0.4 | 0.7582 | 31285270 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.4 | 0.7582 | 22074823 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.4 | 0.7582 | 20711432 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by FACs | NA | 0.4 | 0.7582 | 20630067 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SP assay followed by FACs | NA | 0.4 | 0.7582 | 21720213 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by IF staining and SFA | NA | 0.36 | 1 | 31285270 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | RT-PCR and FACs followed by SFA | NA | 0.36 | 1 | 32066912 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by qPCR | NA | 0.36 | 1 | 29449559 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs | NA | 0.36 | 1 | 24760019 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | FACs followed by SFA | NA | 0.36 | 1 | 21701559 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by FACs | NA | 0.36 | 1 | 20630067 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | 5-Fluorouracil | SP assay followed by FACs | NA | 0.36 | 1 | 30005681 |
| DCLK1 | 2700 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0159 | 31964531 |
| SOX9 | 11204 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0244 | 31964531 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.24 | 0.684 | 21694723 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.24 | 0.684 | 23418515 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.24 | 0.684 | 22074823 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SP assay followed by ALDEFLUOR assay and Tumorigenicity assay | NA | 0.24 | 0.684 | 21720213 |
| ALCAM | 400 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.0583 | 23418515 |
| AXIN2 | 904 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by qPCR | NA | 0.2 | 0.0064 | 29449559 |
| BMI1 | 1066 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.1135 | 32066912 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.5461 | 23418515 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.6448 | 23418515 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.5695 | 23418515 |
| CD4 | 1678 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| CDH2 | 1759 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0085 | 20630067 |
| COL1A1 | 2197 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| DLL1 | 2908 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0032 | 20630067 |
| DTX1 | 3060 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| FGF3 | 3681 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0021 | 20630067 |
| FZD1 | 4038 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0042 | 20630067 |
| IGF1 | 5464 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0053 | 20630067 |
| JAG1 | 6188 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0117 | 20630067 |
| KRT15 | 6421 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0053 | 20630067 |
| MSX1 | 7391 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| NCAM1 | 7656 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0074 | 20630067 |
| NOTCH1 | 7881 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | DLD-1 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0477 | 20630067 |